Dynamics of DLGG and Clinical Implications

  • Emmanuel MandonnetEmail author


Diffuse low-grade glioma is defined by a common morphotype on histological analysis. However, these tumors exhibit a wide heterogeneity in their degree of biological aggressivity, resulting in a large range of survival times. Several factors at diagnosis have been found to identify different subgroups of prognosis, but there is growing evidence that the intrinsic dynamics of the tumor – that can be evaluated over a short initial follow-up – plays a major role in predicting overall prognosis at an individual scale. We will review our current knowledge of DLGG dynamics on molecular, histological, radiological, and clinical scales. In particular, we emphasize the importance of estimating the initial radiological dynamics from two successive morphological MRI. Finally, we describe how the spontaneous dynamics can be modified by the different treatment modalities, including surgery, chemotherapy, and radiotherapy.


Diffuse low-grade glioma Tumor dynamics Tumor kinetics Growth rate 


  1. 1.
    Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, Slotman BJ, Klein M. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol. 2011;29(33):4430–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Alimenti A, Delavelle J, Lazeyras F, Yilmaz H, Dietrich PY, de Tribolet N, Lovblad KO. Monovoxel 1H magnetic resonance spectroscopy in the progression of gliomas. Eur Neurol. 2007;58(4):198–209.PubMedCrossRefGoogle Scholar
  3. 3.
    Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74(6):1784–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, Yan H, Papadopoulos N, Kinzler KW. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333(6048):1453–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Bian W, Khayal IS, Lupo JM, McGue C, Vandenberg S, Lamborn KR, Chang SM, Cha S, Nelson SJ. Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, ­perfusion, and diffusion imaging. Transl Oncol. 2009;2(4):271–80.PubMedGoogle Scholar
  6. 6.
    Brasil Caseiras G, Ciccarelli O, Altmann DR, Benton CE, Tozer DJ, Tofts PS, Yousry TA, Rees J, Waldman AD, Jager HR. Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology. 2009;253(2):505–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2005;26(2):266–73.PubMedGoogle Scholar
  8. 8.
    Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM. Preoperative prognostic classifi­cation system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008;109(5):817–24.PubMedCrossRefGoogle Scholar
  9. 9.
    Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, Mukhopadhyay D, Kim W, Liau LM, Chang SM, Smith JS, Berger MS, McDermott MW. Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg. 2009;111(2):203–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen X, Dai J, Jiang T. Supratentorial WHO grade II glioma invasion: a morphologic study using sequential conventional MRI. Br J Neurosurg. 2010;24(2):196–201.PubMedCrossRefGoogle Scholar
  11. 11.
    Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol. 2008;86(3):321–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Danchaivijitr N, Waldman AD, Tozer DJ, Benton CE, Brasil Caseiras G, Tofts PS, Rees JH, Jager HR. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology. 2008;247(1):170–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP. Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neurooncol. 1997;34(1):61–78.PubMedCrossRefGoogle Scholar
  14. 14.
    Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP. Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol. 1997;34(1):37–59.PubMedCrossRefGoogle Scholar
  15. 15.
    Duffau H, Pallud J, Mandonnet E. Evidence for the genesis of WHO grade II glioma in an asymptomatic young adult using repeated MRIs. Acta Neurochir (Wien). 2011;153(3):473–7.CrossRefGoogle Scholar
  16. 16.
    Duffau H. The challenge to remove diffuse low-grade gliomas while preserving brain functions. Acta Neurochir (Wien). 2012;154(4):569–74.CrossRefGoogle Scholar
  17. 17.
    Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11(12):835–48.PubMedGoogle Scholar
  18. 18.
    Gomori E, Pal J, Kovacs B, Doczi T. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Diagn Pathol. 2012;7(1):8.PubMedCrossRefGoogle Scholar
  19. 19.
    Goze C, Bezzina C, Goze E, Rigau V, Maudelonde T, Bauchet L, Duffau H. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol. 2012;108(1):69–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Guillevin R, Menuel C, Duffau H, Kujas M, Capelle L, Aubert A, Taillibert S, Idbaih A, Pallud J, Demarco G, Costalat R, Hoang-Xuan K, Chiras J, Vallee JN. Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. J Neurooncol. 2008;87(2):181–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Guillevin R, Menuel C, Vallee JN, Francoise JP, Capelle L, Habas C, De Marco G, Chiras J, Costalat R. Mathematical modeling of energy metabolism and hemodynamics of WHO grade II gliomas using in vivo MR data. C R Biol. 2010;334(1):31–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Guillevin R, Menuel C, Abud L, Costalat R, Capelle L, Hoang-Xuan K, Habas C, Chiras J, Vallee JN. Proton MR spectroscopy in predicting the increase of perfusion MR imaging for WHO grade II gliomas. J Magn Reson Imaging. 2011;35(3):543–50.PubMedCrossRefGoogle Scholar
  23. 23.
    Guillevin R, Menuel C, Taillibert S, Capelle L, Costalat R, Abud L, Habas C, De Marco G, Hoang-Xuan K, Chiras J, Vallee JN. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. Br J Cancer. 2011;104(12):1854–61.PubMedCrossRefGoogle Scholar
  24. 24.
    Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F. Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol. 2010;97(1):73–80.PubMedCrossRefGoogle Scholar
  25. 25.
    Ishii N, Tada M, Hamou MF, Janzer RC, Meagher-Villemure K, Wiestler OD, Tribolet N, Van Meir EG. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene. 1999;18(43):5870–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Jbabdi S, Mandonnet E, Duffau H, Capelle L, Swanson KR, Pelegrini-Issac M, Guillevin R, Benali H. Simulation of anisotropic growth of low-grade gliomas using diffusion tensor imaging. Magn Reson Med. 2005;54(3):616–24.PubMedCrossRefGoogle Scholar
  27. 27.
    Jiang Z, Le Bas JF, Grand S, Salon C, Pasteris C, Hoffmann D, Bing F, Berger F, Chabardes S, Liu C, Krainik A. Prognostic value of perfusion MR imaging in patients with oligodendroglioma: a survival study. J Neuroradiol. 2011;38(1):53–61.PubMedCrossRefGoogle Scholar
  28. 28.
    Kier EL, Staib LH, Davis LM, Bronen RA. MR imaging of the temporal stem: anatomic dissection tractography of the uncinate fasciculus, inferior occipitofrontal fasciculus, and Meyer’s loop of the optic radiation. AJNR Am J Neuroradiol. 2004;25(5):677–91.PubMedGoogle Scholar
  29. 29.
    Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24(10):1989–98.PubMedGoogle Scholar
  30. 30.
    Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR, Fitzek MM, Chiocca EA, Rabinov JD, Csavoy AN, Rosen BR, Hochberg FH, Schaefer PW, Gonzalez RG. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 2004;25(2):214–21.PubMedGoogle Scholar
  31. 31.
    Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, Cornu P, Van Effenterre R, Alvord Jr EC, Capelle L. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53(4):524–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Mandonnet E, Capelle L, Duffau H. Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns. J Neurooncol. 2006;78(2):179–85.PubMedCrossRefGoogle Scholar
  33. 33.
    Mandonnet E, Pallud J, Fontaine D, Taillandier L, Bauchet L, Peruzzi P, Guyotat J, Bernier V, Baron MH, Duffau H, Capelle L. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev. 2010;33(1):91–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Mandonnet E, Duffau H, Bauchet L. A new tool for grade II glioma studies: plotting cumulative time with quality of life versus time to malignant transformation. J Neurooncol. 2011;106(1):213–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Martino J, Taillandier L, Moritz-Gasser S, Gatignol P, Duffau H. Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir (Wien). 2009;151(5):427–36; discussion 436.CrossRefGoogle Scholar
  36. 36.
    Matsukado Y, Maccarty CS, Kernohan JW. The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg. 1961;18:636–44.PubMedCrossRefGoogle Scholar
  37. 37.
    McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, Olivi A, Brem H, Quinones-Hinojosa A. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neuro­surgery. 2008;63(4):700–7; author reply 707–8.PubMedCrossRefGoogle Scholar
  38. 38.
    McKnight TR, Lamborn KR, Love TD, Berger MS, Chang S, Dillon WP, Bollen A, Nelson SJ. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg. 2007;106(4):660–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170(5):1445–53.PubMedCrossRefGoogle Scholar
  40. 40.
    Pallud J, Devaux B, Daumas-Duport C, Oppenheim C, Roux FX. Glioma dissemination along the corticospinal tract. J Neurooncol. 2005;73(3):239–40.PubMedCrossRefGoogle Scholar
  41. 41.
    Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, Taillandier L, Capelle L. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60(3):380–3.PubMedCrossRefGoogle Scholar
  42. 42.
    Pallud J, Duffau H, Razak RA, Barbarino-Monnier P, Capelle L, Fontaine D, Frenay M, Guillet-May F, Mandonnet E, Taillandier L. Influence of pregnancy in the behavior of diffuse gliomas: clinical cases of a French glioma study group. J Neurol. 2009;256(12):2014–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Pallud J, Capelle L, Mandonnet E. Comment on parameters of low-grade glioma as predictors. Radiology. 2010;256(3):1014.PubMedCrossRefGoogle Scholar
  44. 44.
    Pallud J, Fontaine D, Duffau H, Mandonnet E, Sanai N, Taillandier L, Peruzzi P, Guillevin R, Bauchet L, Bernier V, Baron MH, Guyotat J, Capelle L. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol. 2010;68(5):727–33.PubMedCrossRefGoogle Scholar
  45. 45.
    Pallud J, Mandonnet E, Deroulers C, Fontaine D, Badoual M, Capelle L, Guillet-May F, Page P, Peruzzi P, Jouanneau E, Frenay M, Cartalat-Carel S, Duffau H, Taillandier L. Pregnancy increases the growth rates of World Health Organization grade II gliomas. Ann Neurol. 2010;67(3):398–404.PubMedGoogle Scholar
  46. 46.
    Pallud J, Varlet P, Devaux B, Geha S, Badoual M, Deroulers C, Page P, Dezamis E, Daumas-Duport C, Roux FX. Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology. 2010;74(21):1724–31.PubMedCrossRefGoogle Scholar
  47. 47.
    Pallud J, Llitjos J, Dhermain F, Varlet P, Dezamis E, Devaux B, Souillard-Scemama R, Sanai N, Koziak M, Page P, Schlienger M, Daumas-Duport C, Meder J, Oppenheim C, Roux F. Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2012;14(4):496–505.PubMedCrossRefGoogle Scholar
  48. 48.
    Pallud J, Mandonnet E. Letter to the Editor: Incidental low-grade gliomas. J Neurosurg. 2012 Dec 21. [Epub ahead of print].Google Scholar
  49. 49.
    Perry JR, Cairncross JG. Glioma therapies: how to tell which work? J Clin Oncol. 2003;21(19):3547–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Peyre M, Cartalat-Carel S, Meyronet D, Ricard D, Jouvet A, Pallud J, Mokhtari K, Guyotat J, Jouanneau E, Sunyach MP, Frappaz D, Honnorat J, Ducray F. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12(10):1078–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol. 2011;2:49.PubMedCrossRefGoogle Scholar
  52. 52.
    Potts MB, Smith JS, Molinaro AM, Berger MS. Natural history and surgical management of incidentally discovered low-grade gliomas. J Neurosurg. 2012;116(2):365–72.PubMedCrossRefGoogle Scholar
  53. 53.
    Pouratian N, Asthagiri A, Jagannathan J, Shaffrey ME, Schiff D. Surgery Insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol. 2007;3(11):628–39.PubMedCrossRefGoogle Scholar
  54. 54.
    Price SJ. Advances in imaging low-grade gliomas. Adv Tech Stand Neurosurg. 2010;35:1–34.PubMedCrossRefGoogle Scholar
  55. 55.
    Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY. Dynamic history of low-grade gliomas before and after ­temozolomide treatment. Ann Neurol. 2007;61(5):484–90.PubMedCrossRefGoogle Scholar
  56. 56.
    Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753–64; discussion 264–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Scherer H. The forms of growth in gliomas and their practical significance. Brain. 1940;63:1–35.CrossRefGoogle Scholar
  58. 58.
    Shah AH, Madhavan K, Heros D, Raper DM, Iorgulescu JB, Lally BE, Komotar RJ. The management of incidental low-grade gliomas using magnetic resonance imaging: systematic review and optimal treatment paradigm. Neurosurg Focus. 2011;31(6):E12.PubMedCrossRefGoogle Scholar
  59. 59.
    Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338–45.PubMedCrossRefGoogle Scholar
  60. 60.
    Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W. Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force. Eur J Neurol. 2010;17(9):1124–33.PubMedCrossRefGoogle Scholar
  61. 61.
    Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, Yoon YH, Lee EJ, Yang MC, Lewis RF, Harris GJ, Lev M, Schaefer PW, Buchbinder BR, Barest G, Yamada K, Ponzo J, Kwon HY, Gemmete J, Farkas J, Tievsky AL, Ziegler RB, Salhus MR, Weisskoff R. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol. 2001;19(2):551–7.PubMedGoogle Scholar
  62. 62.
    van den Bent M, Wefel J, Schiff D, Taphoorn M, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman A, Gorlia T, Chamberlain M, Baumert B, Vogelbaum M, Macdonald D, Reardon D, Wen P, Chang S, Jacobs A. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583–93.PubMedCrossRefGoogle Scholar
  63. 63.
    Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–53.PubMedCrossRefGoogle Scholar
  64. 64.
    Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. 2009;69(24):9157–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.PubMedCrossRefGoogle Scholar
  66. 66.
    Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226(1):7–16.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of NeurosurgeryLariboisière HospitalParisFrance

Personalised recommendations